GLTO vs. TCRT, FLGC, NRSN, BIVI, APM, KALA, HUGE, ADXN, ORGS, and BNTC
Should you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Alaunos Therapeutics (TCRT), Flora Growth (FLGC), NeuroSense Therapeutics (NRSN), BioVie (BIVI), Aptorum Group (APM), KALA BIO (KALA), FSD Pharma (HUGE), Addex Therapeutics (ADXN), Orgenesis (ORGS), and Benitec Biopharma (BNTC). These companies are all part of the "pharmaceutical preparations" industry.
Alaunos Therapeutics (NASDAQ:TCRT) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.
Galecto received 23 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 58.82% of users gave Galecto an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote.
Alaunos Therapeutics has a beta of -0.33, meaning that its stock price is 133% less volatile than the S&P 500. Comparatively, Galecto has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
Galecto has a consensus target price of $5.33, suggesting a potential upside of 716.49%. Given Alaunos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Galecto is more favorable than Alaunos Therapeutics.
Alaunos Therapeutics' return on equity of -93.68% beat Galecto's return on equity.
27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 6.2% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 12.1% of Galecto shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks.
In the previous week, Galecto had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 2 mentions for Galecto and 0 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.56 beat Galecto's score of 0.00 indicating that Galecto is being referred to more favorably in the news media.
Summary
Galecto beats Alaunos Therapeutics on 13 of the 15 factors compared between the two stocks.
Get Galecto News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
